Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLSGet Rating) in a report issued on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on RGLS. Canaccord Genuity Group assumed coverage on shares of Regulus Therapeutics in a research note on Tuesday, November 8th. They issued a buy rating and a $9.00 target price on the stock. Canaccord Genuity Group started coverage on shares of Regulus Therapeutics in a research report on Monday, November 7th. They issued a buy rating and a $9.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Regulus Therapeutics currently has an average rating of Moderate Buy and an average target price of $12.67.

Regulus Therapeutics Stock Up 3.3 %

Regulus Therapeutics stock opened at $1.72 on Monday. The company has a market cap of $25.09 million, a PE ratio of -0.78 and a beta of 1.63. Regulus Therapeutics has a twelve month low of $1.33 and a twelve month high of $4.20. The company’s 50-day moving average price is $1.69 and its 200-day moving average price is $2.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Federated Hermes Inc. purchased a new position in Regulus Therapeutics during the 1st quarter worth $8,656,000. Vanguard Group Inc. grew its stake in Regulus Therapeutics by 21.4% during the 1st quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 648,121 shares during the last quarter. Northern Trust Corp grew its stake in Regulus Therapeutics by 42.9% during the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 50,518 shares during the last quarter. Renaissance Technologies LLC grew its stake in Regulus Therapeutics by 498.2% during the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 111,100 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Regulus Therapeutics by 108.5% during the 3rd quarter. BlackRock Inc. now owns 45,614 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 23,738 shares during the last quarter. 59.60% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

(Get Rating)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Further Reading

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.